Here we provide a selection of scientific publications related to IOZK immunotherapy. You can use the filters to make a selection according to tumor types and methods, or enter search terms.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-03-10 / Front Oncol 2020;10:254https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-03-10 / Front Oncol 2020;10:2542020-03-10 00:00:002020-08-26 14:24:04Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-03-06 / Cancers (Basel) 2020 Mar;12(3)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-03-06 / Cancers (Basel) 2020 Mar;12(3)2020-03-06 00:00:002020-03-06 00:00:00Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-03-05 / Cancers (Basel) 2020 Mar;12(3)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-03-05 / Cancers (Basel) 2020 Mar;12(3)2020-03-05 00:00:002020-08-26 13:47:31Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-03-04 / Biomed. Pharmacother. 2020 Jun;126:110046https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-03-04 / Biomed. Pharmacother. 2020 Jun;126:1100462020-03-04 00:00:002020-03-04 00:00:00Dendritic cell vaccine for the effective immunotherapy of breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-03-01 / J Immunother Cancer 2020 03;8(1)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-03-01 / J Immunother Cancer 2020 03;8(1)2020-03-01 00:00:002022-09-29 14:17:36Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-03-01 / J Immunother Cancer 2020 Mar;8(1)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-03-01 / J Immunother Cancer 2020 Mar;8(1)2020-03-01 00:00:002020-03-01 00:00:00T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-02-22 / Cancer Immunol. Immunother. 2020 Jun;69(6):1015-1027https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-02-22 / Cancer Immunol. Immunother. 2020 Jun;69(6):1015-10272020-02-22 00:00:002020-08-26 14:19:05Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-02-21 / Front Oncol 2020;10:187https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-02-21 / Front Oncol 2020;10:1872020-02-21 00:00:002020-02-21 00:00:00Immunotherapy in Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e18889https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e188892020-02-01 00:00:002020-02-01 00:00:00Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S119https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S1192020-02-01 00:00:002020-12-09 09:48:40Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-02-01 / J Immunother Cancer 2020 02;8(1)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-02-01 / J Immunother Cancer 2020 02;8(1)2020-02-01 00:00:002020-02-01 00:00:00TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia
New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification
Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
Dendritic cell vaccine for the effective immunotherapy of breast cancer
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
[The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells]
Immunotherapy in Malignant Pleural Mesothelioma
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
Feasibility of modulated electro-hyperthermia in preoperative treatment for locally advanced rectal cancer: Early phase 2 clinical results
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines